US Senator Durbin criticizes delayed FDA e-cigarette review.

May.23.2022
US Senator Dick Durbin criticized the FDA for delaying the public health review of tobacco products before electronic cigarettes hit the market.

During a speech in the Senate, US Senator Dick Durbin criticized the FDA for delaying completion of the public health review of tobacco product applications (PMTA) prior to the launch of electronic cigarettes. The deadline for the FDA to complete review of e-cigarette applications was over eight months ago on September 9th, 2021.

 

The FDA announced on June 13th that it has filed the latest update on its review of electronic cigarette applications, stating that the review process will not be completed until July 2023. Products currently under review may still be available for sale.

 

These companies are saturating the market with addictive devices. Companies like Juul, which are partially owned by tobacco companies, understand that they are marketing their products to children," said Durbin during a press conference in his office. "For years, these products haven't been authorized by law. Who should regulate them? The FDA, but currently, there is no regulation.

 

In March of this year, Senator Durbin and 14 of his colleagues wrote a bipartisan letter calling on the FDA to immediately complete its review of e-cigarettes and reject any applications, particularly those with flavors marketed to children, that do not prove to be beneficial for public health. The letter also urged the removal of all unapproved e-cigarettes from the market.

 

Senator Durbin stated, "I urge the FDA to immediately put an end to their enforcement discretionary power and remove all unauthorized e-cigarettes from the market. Let's not let Juul and other tobacco companies continue to endanger our children for another day. Let's not cower in front of high-paid tobacco lawyers again.

 

Source: Tobacco Reporter

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan lawmakers introduced Senate Bill 786 on February 18, 2026, proposing to prohibit the sale or transfer of vapor products that contain heating elements unless those elements are made of or encased in glass or ceramic materials
Regulations
Feb.21
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Singapore detected 59 large-scale vape smuggling cases in 2025, seizing about 230,000 items
Singapore detected 59 large-scale vape smuggling cases in 2025, seizing about 230,000 items
Singapore’s Ministry of Health said on Feb. 3 that authorities detected 59 large-scale vape smuggling cases in 2025 and seized about 230,000 vapes and accessories. Over the past two years, more than 10,000 online vape sale advertisements were removed, with about 99% linked to overseas platform posts. Enforcement includes bot-driven surveillance, public tip-offs, and site-blocking with partner agencies.
Feb.04 by 2FIRSTS.ai
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK specialist vape retailer VPZ has launched a multi-million-pound investment programme to boost domestic production capacity and tighten supply-chain controls. The plan includes adding a fifth production line, opening 40 new stores across the UK in 2026 and creating hundreds of jobs, while establishing a bonded warehouse at its Edinburgh headquarters as regulation tightens and a vaping tax is planned.
Feb.02 by 2FIRSTS.ai
Russia considers digital tagging for e-cigarette products to strengthen industry regulation
Russia considers digital tagging for e-cigarette products to strengthen industry regulation
Russia is considering digitizing e-cigarette products for better industry regulation, aiming to protect consumers and prevent counterfeit products.
Feb.05 by 2FIRSTS.ai